Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase Iand II xenobiotic metabolizing enzymes
A. Bishayee et al., Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase Iand II xenobiotic metabolizing enzymes, BREAST CANC, 63(2), 2000, pp. 133-145
Vanadium, a non-platinum group metal and dietary micronutrient, is now prov
ing to act as a promising antitumor agent. The present study was conducted
to ascertain its antineoplastic potential against an experimental mammary c
arcinogenesis. Female Sprague-Dawley rats, at 50 days of age, were treated
with 7,12-dimethylbenz(a)anthracene (DMBA) (0.5 mg/100 g body weight) by a
single tail vein injection in an oil emulsion. Vanadium (ammonium monovanad
ate) at the concentration of 0.5 ppm was supplemented in drinking water and
given ad libitum to the experimental group immediately after the carcinoge
n treatment and it continued until the termination of the study (24 weeks f
or histological and biochemical observations and 35 weeks for morphological
findings). It was found that vanadium treatment brought about a substantia
l protection against DMBA-induced mammary carcinogenesis. This was evident
from histological findings that showed no sign of hyperplasia or abnormalit
y after vanadium treatment. There was a significant reduction in incidence
(P < 0.05), total number, multiplicity (P < 0.01) and size of palpable mamm
ary tumors and delay in mean latency period of tumor appearance (P < 0.001)
following vanadium supplementation compared to DMBA control. From the cumu
lative results of various hepatic biochemical indices namely, lipid peroxid
ation, reduced glutathione level, superoxide dismutase activity, cytochrome
P450 content and glutathione S-transferase activity, the anticarcinogenic
potential of vanadium was well reflected through stabilization of these par
ameters. Results of the study indicate that the anticarcinogenic activity o
f vanadium during DMBA-initiated mammary carcinogenesis is mediated through
alteration of hepatic antioxidant status as well as modulation of phase I
and II drug metabolizing enzymes. On the basis of the observed results, van
adium can be considered as a readily available, promising and novel cancer
chemopreventive agent.